CSOs and patient groups welcomes IPO's rejection of patent for multi-drug resistant regimen BPaL: Our Bureau, New Delhi Wednesday, October 28, 2026, 14:10 Hrs [IST] Patient groups ...
Pfizer announces positive results from phase 3 MagnetisMM-32 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Wednesday, October 2 ...
This November, Hyderabad will bring together some of the biggest names in the pharma world, as the Global Pharma Partnering Summit 2026 confirms its speakers and participants ahead of its 2–3 November ...
TN IDMA elects new office-bearers; J Jayaseelan elevated to IDMA South Zone vice-president: Peethaambaran Kunnathoor, Chennai Wednesday, October 28, 2026, 08:00 Hrs [IST] In a maj ...
Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA: Our Bureau, New Delhi Wednesday, ...
KPRDO asks Micro Labs to immediately halt direct supply practices and discriminatory trade schemes: Nandita Vijayasimha, Bengaluru Wednesday, October 28, 2026, 08:00 Hrs [IST] The ...
Sightsavers India collaborates with govt to integrate vision centres with UPHCs to support NHM: Shardul Nautiyal, Mumbai Wednesday, October 28, 2026, 08:00 Hrs [IST] Sightsavers I ...
The Central Drugs Standard Control Organisation (CDSCO) has cancelled the registration certificate of a Delhi-based importer, Tekno Midas Aesthetics, to import a cosmetic product FatX solution claimed ...
Periodic training plays an important role for product launches in pharma marketing: Shiladitya Mallik: Yash Ved, Mumbai Wednesday, October 28, 2026, 08:00 Hrs [IST] Tighter market ...
Abbott introduces whole-genome sequencing Oncodetect MRD test to detect traces of cancer during and after treatment: Abbott Park, Illinois Wednesday, October 28, 2026, 16:00 Hrs [ ...
Cipla Limited announced its unaudited consolidated financial results for the quarter ended September 30, 2026. The company's Income from operations stood at Rs. 7,404 crore, while PAT stood at Rs. 878 ...
China NMPA grants marketing authorization to Bayer’s asundexian, a selective, once-daily oral Factor XIa inhibitor to reduce risk of stroke: Berlin Wednesday, October 28, 2026, ...